← Search

Omics · study · 2026

Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy

Listed in NCBI GEO

HER2 is a frequently overexpressed gene in biliary tract cancer (BTC).

Description

Although several targeted agents, including trastuzumab, have been approved for the treatment of BTC, their clinical efficacy remains limited. To explore this issue, we treated two BTC cell lines—SNU1196 and GBC-SD—with different anti-HER2 agents.

We then performed gene expression profiling analysis using data from RNA-seq of 2 different cells treated with different drugs.

Links

Topics

From keywords
Life Sciences
Inferred from text
Cancer 75% · RNA sequencing 65%
Provenance · 1 source records, 9 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE31590614 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[disease].local:disease:cancerenrichment · NCBI GEOkeyword-concept-rules@1.0.0title+description (75%)
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[modality].local:modality:rna-seqenrichment · NCBI GEOkeyword-concept-rules@1.0.0title+description (65%)
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title